It may just be a buy here…. well, for those of you that like living on the edge of your seat.
Granted, it’s not the prettiest trend we’ve ever seen, but if this Thursday turns out well, upside is likely.
Thursday is when Human Genome releases it Q2 2011 earnings, the day investors will learn if its Benlysta drug (a potential blockbuster drug for the treatment of lupus) is being prescribed well.
According to reports, “Analysts estimate the drug had just under $9 million in sales in the second quarter. Raymond thinks that number will be $10 million. For full-year sales, Raymond is way above the consensus estimate. He predicts 2011 revenue of $103 million for the drug, compared with a consensus number of about $77 million. Raymond bases his target on feedback from doctors Baird surveys.”
